Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancer

ABSTRACT: Interventions: FOLFOXIRI+cetuximab (until 12 courses) Cetuximab 400mg/m2/weekly (initial dose) 250mg/m2/weekly (maintenance) Irinotecan 100-150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Recommended dose Study Design: Single arm Non-randomized

DISEASE(S): Ras Wild-type Unresectable Colorectal Cancer

PROVIDER: 2630948 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR